Comment
doi: 10.1016/S1474-4422(18)30496-4.
CVT-301 for Parkinson's disease: dose and effect size issues
Affiliations
- PMID: 30663600
- DOI: 10.1016/S1474-4422(18)30496-4
Item in Clipboard
Comment
CVT-301 for Parkinson's disease: dose and effect size issues
Lancet Neurol.
2019 Feb.
No abstract available
Comment on
-
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.Lancet Neurol. 2019 Feb;18(2):145-154. doi: 10.1016/S1474-4422(18)30405-8. Lancet Neurol. 2019. PMID: 30663606 Clinical Trial.
Similar articles
-
Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson's disease.Expert Opin Drug Metab Toxicol. 2018 Dec;14(12):1189-1195. doi: 10.1080/17425255.2018.1550483. Epub 2018 Dec 2. Expert Opin Drug Metab Toxicol. 2018. PMID: 30479171 Review.
-
The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.CNS Drugs. 2004;18(11):733-46. doi: 10.2165/00023210-200418110-00003. CNS Drugs. 2004. PMID: 15330687 Clinical Trial.
-
Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.Mov Disord. 2016 Apr;31(4):530-7. doi: 10.1002/mds.26528. Epub 2016 Jan 28. Mov Disord. 2016. PMID: 26817533 Free PMC article. Clinical Trial.
-
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary.BMJ. 1996 Mar 16;312(7032):702-3; author reply 704-5. BMJ. 1996. PMID: 8597746 Free PMC article. No abstract available.
-
Does levodopa slow or hasten the rate of progression of Parkinson's disease?J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42. doi: 10.1007/s00415-005-4008-5. J Neurol. 2005. PMID: 16222436 Review.
Cited by
-
Efficacy and safety of safinamide in Parkinson's disease patients with motor fluctuations without levodopa dosage escalation over 18 weeks: KEEP study.J Neural Transm (Vienna). 2025 Mar;132(3):431-441. doi: 10.1007/s00702-024-02851-6. Epub 2024 Nov 14. J Neural Transm (Vienna). 2025. PMID: 39540934 Free PMC article.
-
Off-time Treatment Options for Parkinson's Disease.Neurol Ther. 2023 Apr;12(2):391-424. doi: 10.1007/s40120-022-00435-8. Epub 2023 Jan 12. Neurol Ther. 2023. PMID: 36633762 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
